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ABSTRACT
EnTkephalins are pentapeptides with opioid activity which are found in a
wide variety of tissues. Studies of enkephalin-containing peptides from
the adrenal gland have established that the mature pentapeptides are derived
by proteolytic processing of a precursor protein. We have shown that human
adrenal medullary tumours contain mRNA which can be translated in vitro to
yield a single major enkephalin precursor. The sequence of cloned cDNA
shows that the preproenkephalin mRNA encodes four copies of met-enkephalin,
two copies of met-enkephalin extended sequences and one copy of leu-
enkephalin; each copy is flanked by paired basic amino acids which are
presumably recognised by the processing protease. We have used the cloned
human cDNA as a hybridisation probe to detect the corresponding mRNAs in rat
adrenal gland and, in smaller amounts, in rat brain. We have been unable to
detect in brain any other cross-hybridising mRNAs which might encode other
putative precursor proteins.
INTRODUCTION
Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and leu-enkephalin (Tyr-Gly-Gly-Phe
-Leu) are pentapeptides which compete with and mimic the effects of opiate
drugs (1). Although interest in enkephalins stems largely from their
possible role in the brain, the richest source of these peptides is the
adrenal gland (2) and most work has concentrated on this tissue. Analyses
of enkephalin-containing peptides isolated from adrenal glands indicate that
the peptides are derived by proteolytic cleavage of a precursor protein (3).
The most direct route to the structure of this proenkephalin is to clone and
sequence cDNA copies of the relevant mRNA. We hoped that such an approach
might, in addition to defining the structure of proenkephalin, also lead
to the characterisation of novel peptide hormones found within the same
precursor, as occurred previously in the case of pro-opiomelanocortin (4).
Moreover, the availability of a cloned probe would enable us to study
enkephalin synthesis in brain from which it is difficult to obtain
sufficient material for direct peptide analysis.
Although most previous work has concentrated on the proenkephalin of
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the bovine adrenal gland, we decided, in view of the possible role of
enkephalins in pain control and in psychiatric disease (5), to study the
corresponding human protein. Phaeochromocytomas, which are tumours of the
human adrenal medulla, synthesise very large amounts of enkephalin (6) and
therefore seemed likely to be a useful source of the corresponding mRNA.
We have used in vitro translation techniques to show that such tumours
synthesise a single major enkephalin precursor and have cloned and
sequenced the cDNA encoding this protein thus defining the complete
structure of a human preproenkephalin. The cloned cDNA has been used as a
probe in transfer hybridisation experiments to analyse enkephalin precursor
synthesis in rat adrenal gland and brain.
MATERIALS AND METHODS
Nucleic Acids. The DNAs of plasmid vectors and of recombinant plasmids were
isolated by the alkaline lysis procedure of Birnboim and Doly (7) from
saturated cultures of appropriate strains of Escherichia coli. The plasmid
vector pCD5 (M.R.D. Scott and P.W.J. Rigby, manuscript in preparation) is
derived from pXf3 (D. Hanahan, personal communication). pXf3 is derived
from pBR322 by two deletions, from nucleotide 1426 to nucleotide 2521 and
from nucleotide 3102 to nucleotide 3223 in the sequence of Sutcliffe (8).
To construct pCD5 a further deletion, encompassing nucleotides 380 to 649,
was introduced. This has the effect of relocating the single SaII site of
pBR322 to be only six nucleotides from the single BanI site. cDNA inserted
between the HindIII and BamI sites of pCD5 can then be excised by digestion
with SaII (or TaqI) and ClaI (or EcoRI). Plasmid DNAs were labeled with
32 in vitro by nick translation (9). Oligonucleotides were labeled to
specific activities of approximately 2 x 108 c.p.m./1g in 50l reactions
containing lpg of oligonucleotide, 2.6pM [y32P]ATP (>3,000 Ci/mmole, Amersham
International), 5 units of T4 polynucleotide kinase (Boehringer Mannheim)
and the buffer described by Maxam and Gilbert (10). After 30 min. at 370C
the oligonucleotides were separated from unincorporated ATP by gel filtration
on columns of Sephadex G25 run in lOmM Tris HCI, pH7.5, lOOmM NaCl, lmM EDTA
(TSE).
mRNA was isolated from frozen tissue by grinding it to a powder under
liquid nitrogen and then dispersing it in lOOmM NaCl, lmM MgCl2, 1mM
spermidine, 2mg./ml. heparin, 0.5% (v/v) NP40. Nuclei were removed by
centrifugation at 5,000rpm. for 5 min. at 40C in a Sorvall HB4 rotor and the
supernatant was adjusted to be 1% (w/v) in SDS and lOmM in EDTA and then
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extracted with phenol. RNA was precipitated from the aqueous phase with
ethanol and polyadenylated RNA was selected by either two cycles of
chromatography on oligodT-cellulose (tumours C and M and all brain RNAs) or
a single cycle on polyU-sepharose (tumour B and rat adrenal RNA). mRNA was
isolated from cultured KBG cells by extraction of cell lysates with hot
phenol (M.R.D. Scott and P.W.J. Rigby, manuscript in preparation).
In vitro Translation Assay for Proenkephalin mRNA. Translation was
performed in a nuclease-treated rabbit reticulocyte lysate (11) in the
presence of lmCi/ml. [35S]methionine (Amersham International) and 50wg./ml.
mRNA. Translation products were analysed by SDS-polyacrylamide gel
electrophoresis (12). Proteins eluted (13) from slices of such gels were
dissolved in 200l 5cnM Tris HCI, pH8.0. Methionine residues were oxidised
to the sulphoxide by adjusting the solution to be 1M in H202 and incubating
at room temperature for lh. Excess peroxide was removed by boiling for 10
min. and adjusting the solution to be lOOmM in DTT. The samples were then
made lmM in CaCl2 and digested with 50iig./ml. trypsin (TLCK-treated,
Worthington) for 2h. at 370C. After inactivating the trypsin by boiling for
5 min. the peptides were further digested with 20Qg./ml. carboxypeptidase B
(Sigma) for 1.5h at 370C and the second enzyme was similarly inactivated.
Samples were diluted twofold in NENT buffer (lOmM Tris HC1, pH8.C, 150mM
NaCl, 0.1mM EDTA, 0.05% (v/v) NP40) and split into two equal aliquots which
were incubated overnight at 40C with ll of either control serum or anti-met-
enkephalin-sulphoxide (14) antiserum.- Immunoprecipitates were collected on
inactivated S. aureus bacteria (15), washed five times in NENT buffer and
then eluted by boiling in 1% (w/v) SDS, lOOmM 2-mercaptoethanol. The eluted
radioactivity was measured by scintillation counting.
cDNA Cloning Procedures. cDNA was synthesised from mRNA from a human adrenal
medullary phaeochromocytoma (tumour B) as follows. bOug polyadenylated RNA
was reverse transcribed in a 20001 reaction containing 50mM Tris HC1, pH8.3,
50mM ammonium acetate, 6mM MgCl2, 1 lnM DTT, 5ug/ml. oligodT, l00ug/ml.
actinomycin D, 1mM each of dATP, dGTP and TTP, 200pM [a32P]dCTP, 200 units
human placental RNase inhibitor (Biotec Inc., Madison, Wisconsin) and 100
units AMV reverse transcriptase (Life Sciences Inc., St. Petersburg, Florida).
After 2h. at 420C the reaction- mixture was adjusted to be lOmM in EDTA and
0.1% (w/v) in SDS and incubated for a further 15 min. with b,ug proteinase K
(British Drug Houses). It was then adjusted to be 0.3N in NaOH, incubated
for 30 min. at 600C, neutralised by the addition of solid MOPS buffer and
deproteinised by extraction with phenol/chloroform. Phenol was removed by
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ether extraction and the cDNA was purified by gel filtration on a 2ml.
column of Sephadex G100 run in TSE buffer. The second cDNA strand was
synthesised using the large subfragment of E. coli DNA polymerase I and self-
priming (16). The terminal hairpin loops were cleaved with endonuclease Sl
(Sigma) and the cDNA was tailed (17) with approximately 25 dGMP residues
using terminal transferase (Ratliff Biochemicals, Los Alamos, New Mexico).
DNA of the plasmid vector pCD5 was digested with BstI and HindIII and tailed
with a similar number of dCMP residues. cDNA and vector were annealed in
TSE buffer at an initial temperature of 650C with cooling to 40°C over 4h.
The resultant hybrid DNA molecules were introduced by transformation into
competent E. coli DH1 cells (D. Hanahan, personal communication) using a
transformation protocol developed in this laboratory (M.R.D. Scott and
P.W.J. Rigby, manuscript in preparation). Transformants were plated
directly onto nitrocellulose filters, selection being for the ampicillin
resistance determinant of pCD5. We obtained 20,000 clones from 0.3wg cDNA;
these were generally grown at a density of 3,000 colonies per 90mm plate.
Replica filters were prepared for screening as described by Hanahan and
Meselson (18).
DNA Sequencing. The chemical sequencing procedures of Maxam and Gilbert (10)
were employed. DNA fragments were labeled at the vector EcoRI and SaII
sites by incubating the fragments (50g/ml.) in 50mM Tris HC1, pH8.3, 6mM
magnesium acetate, 20mM DTT, 0.5pM (ac32P]dNTP (>3,000 Ci/mmole, Amersham
International) and 40 units/ml. reverse transcriptase. When necessary,
unlabeled triphosphate was present at 250pM. Labeling at SmaI or PstI sites
in the cDNA insert was performed by incubating DNA (500g/ml) in 30mM
Tris HC1, pH7.4, 140mM potassium cacodylate, lmM CoCl2, 1mM DTT, 1PM [a 32P]
cordycepin (Amersham International) and 0.5 units/pl terminal transferase
(19).
Transfer Hybridisation. RNAs were fractionated by electrophoresis in 1.2%
(w/v) agarose gels containing formaldehyde and then transferred to
nitrocellulose filters (20). Human, yeast and Drosophila rRNAs were used as
size markers. Hybridisations with oligonucleotide probes (approximately
2ng/ml.) were performed in lOmM Tris HC1, pH7.5, 500mM NaCl, 1mM EDTA, 1 x
Denhardt's solution (21), 100puM ATP at 150C for 16h. Filters were washed in
several changes of hybridisation buffer at 250C for 2h. Hybridisations with
plasmid DNA probes were performed in 5 x SSC, 50% (v/v) formamide, 0.1% (w/v)
SDS, 1 x Denhardt's solution at 420C or 300C, as indicated, for 16h. Filters
were washed in hybridisation buffer at 300C for lh. then in 1 x SSC (150mM
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NaCl, 15mM trisodium citrate) at 300C for lh. In some cases, indicated in
the figure legends, filters were subsequently washed in 1 x SSC for 10 min.
at a higher temperature.
RESULTS
In vitro Translation Assay for Proenkephalin mRNA. The ability to synthesise
proenkephalin in vitro could provide a means of screening cDNA clones and
would also be of value in comparing the primary translation products of
adrenal gland and brain mRNAs. In developing such an assay we have used mRNA
from human adrenal medullary phaeochromocytomas, since such tumours over-
produce enkephalins (6) and are thus likely to be a rich source of
proenkephalin mRNA. Unfortunately, none of the many anti-enkephalin antisera
that we have tested immunoprecipitate proenkephalin and we have therefore
had to resort to an indirect assay which depends upon the fact that
enkephalins can be liberated from proenkephalin by digestion with trypsin
and carboxypeptidase B. The in vitro translation products were fractionated
by electrophoresis in an SDS-polyacrylamide gel, eluted from slices and
digested to release enkephalins for immunoassay. Figure 1 shows that we
detect a single peak of immunoprecipitable met-enkephalin-sulphoxide
corresponding to a proenkephalin of apparent molecular weight 36,500. This
peak represents 1% of the total methionine incorporated into protein and
the sensitivity of this assay allows detection of proenkephalin in
unfractionated in vitro translation products (data not shown). These data
66053K 43K 1K
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Figure 1. Synthesis of psgenkephalin in vitro in response tophaeochromocytoma mRNA. [ S]methionine-labeled proteins were fractionated
by SDS-polyacrylamide gel electrophoresis and enkephalin sequences were
located by radioimmunoassay. Marker proteins were: BSA (68k), catalase
(60k), glutamate dehydrogenase (53k), ovalbumin (43k) and globin (17k).
0 0, anti-enkephalin serum; 0- 0, control serum.
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gave us an estimate of the abundance of proenkephalin mRNA and defined the
size of the precursor protein. Using this procedure we were unable to detect
enkephalin amongst the in vitro translation products of whole rat brain RNA.
Synthetic Oligonucleotide Probes for Proenkephalin Coding Sequences. Although
the in vitro translation assay could be used to screen cDNA clones a more
direct screening protocol was afforded by the observation that bovine adrenal
gland proenkephalin contains the sequence Trp-Trp-Met-Asp-Tyr (22), which is
highly favourable for oligonucleotide synthesis. We reasoned that this
unusual sequence was likely to be conserved between the bovine and human
proteins and therefore used the corresponding oligonucleotides, TAATCCATCCACC
and TAGTCCATCCACC, as hybridisation probes. The labeled oligonucleotides were
used as probes in transfer hybridisation experiments to detect proenkephalin
mRNA in electrophoretically fractionated phaeochromocytoma RNA (Figure 2).
At equivalent autoradiographic exposures one of the oligonucleotides
(TAGTCCATCCACC) gave a strongly hybridising band at about 1.4Kb while the
other hybridised only weakly. This mRNA is not present in a control RNA
from the human tumour cell line KBG and is of an appropriate size to code
for the proenkephalin detected by in vitro translation.
A B C
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Figure 2. Transfer hybridisation analysis of phaeochromocytoma mRNA.
Panel A: Hybridisation with 32P-labeled TAGTCCATCCACC; samples were, (1)
DNA size markers; (2) phaeochromocytom 2RNA; (3) KBG RNA; (4) DNA size
markers. Panel B: Hybridisation with P-labeled TAATCCATCCACC; samples as
in Panel A. Panel C: Hybridisation at 420C with 32P-labeled
preproenkephalin cDNA clone; samples were, (1) KBG RNA; (2) tumour C RNA;




The oligonucleotide TAGTCCATCCACC was therefore labeled and used to
screen a library of 20,000 cDNA clones derived from phaeochromocytoma mRNA.
30 positive signals were obtained (Figure 3). One positive signal came
from a filter carrying only 300 colonies (Figure 3A) and the relevant colony
could thus be picked from the master plate. In the other cases the colony
density was tenfold higher and a second round of screening was required.
Plasmid DNA was isolated from the clone picked from the low density plate,
labeled and hybridised to gel-fractionated phaeochromocytoma mRNA (Figure
2C). The cloned cDNA and the oligonucleotide detect mRNAs of the same size.
The additional faint bands in Figure 2C are due to hybridisation of the
dG:dC tails in the plasmid to contaminating rRNA.
It is clear that the abundance of proenkephalin mRNA varies
considerably between different tumours (Figure 2C). Such variation accounts
for the discrepancy between the frequency (1 in 700) at which we recovered
proenkephalin cDNA clones from a library constructed from mRNA from tumour B
and our estimate (1%) of the abundance of proenkephalin mRNA, which derives
from in vitro translation of mRNA from tumours C and M.
Sequence Analysis of Cloned Proenkephalin cDNA. We first determined the
size of the cDNA insert in each of our thirty clones. This was straight-
forward because the structure of the plasmid vector pCD5 allows the insert to
be excised by digestion with EcoRI and SaII. This structural feature of
A B
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Figure 3. Colony screening with labeled oligonucleotides. Filter A
carried 300 colonies, one of which was positive; FiltsE B carried 3000
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Figure 4. DNA sequencing strategy. The entire sequence is shown in the
top line with the translated region cross-hatched. Sites at which labeling
was performed are indicated thus: * , SailI; X, EcoRI; 6, PstI; 0, SmaI.
Fragments labeled at the vector SaII and EcoRI sites were derived from
different clones, those labeled at PstI and SmaI sites from the largest
clone. 5' and 3' indicate the sense of the mRNA.
the vector was also exploited in designing our sequencing strategy (Figure
4). Because the cDNA inserts are of different lengths the clones themselves
provide the overlapping series of DNA fragments required for sequencing.
Most of the sequence could thus be determined by sequencing from the
AATTGGCCTGCTCCATCCGAACAGCGTCAACTCC ATG GCG CGG TTC CTG ACA CTT TGC ACT TGG CTG CTG TTG CTC GGC CCC GGG CTC
Met Ala Arg Phe Leu Thr Lou Cys Thr Trp Leu Lou Leu Lou Gly Pro Gly Leu
CTG GCG ACC GTG CGG GCC GAA TGC AGC CAG GAT TGC GCG ACG TGC AGC TAC CGC CTA GTG CGC CCG GCC GAC ATC AAC TTC
Lou Ala Thr Val Arg Ala Glu Cys Ser Gin Asp Cys Ala Thr Cys Ser Tyr Arg Leu Vol Arg Pro Al. Asp Ile Asn Phe
CTG GCT TGC GTA ATG GAA TGT GAA GGT AAA CTG CCT TCT CTG AAA ATT TGG GAA ACC TGC AAG GAG CTC CTG CAG CTG TCC
Lou Ala Cys Vol Met Glu Cys Glu Gly Lys Leu Pro Ser Leu Lys Ile Trp Glu Thr Cys Lys Glu Lou Leu Gln Leu Ser
AAA CCA GAG CTT CCT CAA GAT GGC ACC AGC ACC CTC AGA GAA AAT AGC AAA CCG GAA GAA AGC CAT TTG CTA GCC AAA AGG
Lys Pro Glu Leu Pro Gin Asp Gly Thr Ser Thr Leu Arg G6u Asn Ser Lys Pro Glu Glu Ser His Lou Lou Ala Lys Arg
TAT GGG GGC TTC ATG AAA AGG|TAT GGA GGC TTC ATG AAG AAA ATG GAT GAG CTT TAT CCC ATG GAG CCA GAA GAA GAG GCC
Tyr Gly Gly Phe Met Lys Arg Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Not Glu Pro Glu Glu Glu Ala
AAT GGA AGT GAG ATC CTC GCC AAG CGG TAT GGG GGC TTC ATG AAG AAG GAT GCA GAG GAG GAC GAC TCG CTG GCC AAT TCC
Asn Gly Ser Glu Ile Leu Ala Lys Arg Tyr Gly Gly Phe Met Lys Lys Asp Ala Glu Glu Asp Asp Ser Lou Ala Asn Ser
TCA GAC CTG CTA AAA GAG CTT CTG GAA ACA GGG GAC AAC CGA GAG CGT AGC CAC CAC CAG GAT GGC AGT GAT AAT GAG GAA
Ser Asp Leu Lou Lys Glu Leu Leu Glu Thr Gly Asp Asn Arg Glu Arg Ser His His Gin Asp Gly Ser Asp Asn G6u G6u
GAA GTG AGC AAG AGA TAT GGG GGC TTC ATG AGA GGC TTA AAG AGA AGC CCC CAA CTG GAA GAT GAA GCC AAA GAG CTG CAG
Glu Vol Sor Lys Arg Tyr Gly Gly Phe Met Arg Gly Leu Lys Arg Ser Pro Gin Leu Glu Asp Glu Ala Lys Glu Lou Gin
AAG CGA TAT GGGGGC TTC ATG AGA AGA GTA GGT CGC CCA GAG TGG TGG ATG GAC TAC CAG AAA CGG TAT GGAGOT TTC CTG
Lys Arg Tyr Gly Gly Phe Met Arg Arg Vol Gly Arg Pro Glu Trp Trp Nat Asp Tyr Gin Lys Arg LTyr 1ly Gly Ph Lou
AAG CGC TTT GCC GAG GCT CTG CCC TCC GAC GAA GAA GGC GAA AGT TAC TCC AAA GAA GTT CCT GAA ATG GAA AAA ABA C
Lys Arg Phe Ala Glu Ala Lou Pro Ser Asp Glu Glu Gly Glu Sor Tyr Ser Lys Glu Val Pro Glu Not G6u Lys Arg T,r
GGA GCA TTT ATG AGA TTT TAATATTTTTCCCACTAGTGGCCCCAGGCCCCAGCAAGCCTCCCTCCATCCTCCAGTGGGAAACTGTTGATGOTGTTTTATT
Gly> Cly Phe Not Arg Phe|
GTCA2TGTGTTCCTTGCCTTGTATAGTTGAC TTCATTGTCTGGATAACTATACAAC CTGAAAACTGTCAT TTCA66TTCTGTGCTCTTTTTGCA6T CTTTAAGCTCAG
TATT
Figure 5. Sequence of human preproenkephalin. Enkephalin sequences are




flanking vector sites into the inserts carried by a series of the clones.
The remainder of the sequence was determined by labeling at internal
restriction sites (Figure 4). It is 1,028 base pairs in length and includes
the entire coding sequence of preproenkephalin (Figure 5).
Preproenkephalin mRNA in Rat Adrenal Gland and Brain. The predicted amino
acid sequence of human adrenal preproenkephalin accounts for all of the
precursor peptides detected in adrenal gland and most of those from brain.
However, it has been reported that brain contains a proenkephalin of
apparent molecular weight 92,000 (23). Such a protein could be derived
from the same genomic sequence as the adrenal gland precursor if
differential splicing were to operate, it could be the product of a distinct
but evolutionarily related gene or it could be the result of convergent
evolution and have no sequence homology to the preproenkephalin we have
characterised. To explore the synthesis of preproenkephalin in brain we
A 2 3 B
I
Figure 6. Transfer hybridisation analysis of rat adrenal gland and brain
miRNA7Tanel A: samples are, (1) human phaeochromocytoma mRNA~ (2) rat
adrenal gland mRNA; (3) rat brain mRNA. Hybridisation with 3 P-labeled
human preproenkephalin cDNA was at 300C; the final wash was at 450C.
Track 1 was exposed for a shorter time than tracks 2 and 3. Panel B: rat




have used our cDNA clone to probe brain RNA in transfer hybridisation
experiments.
Suitable human tissue was not readily available so we chose to analyse
mRNA from rat adrenal gland and brain. Figure 6A shows that in rat adrenal
gland mRNA there are two prominent bands, one the same size as human adrenal
gland preproenkephalin mRNA, the other slightly larger, about 1.6Kb. This
latter RNA is also found in rat brain but has no counterpart in human
adrenal glands. Other, faint, bands are also observed. However,
hybridisation with labeled, tailed vector shows that all bands apart from
that of the same size as human adrenal gland preproenkephalin mRNA result
from hybridisation to the oligo dG:dC tails in the recombinant plasmid. The
background due to these artefactual hybridisations can be greatly reduced by
washing the filters at higher temperatures. In this way we were able to
detect in rat striatum, the part of the brain richest in enkephalin (31), an
mRNA of the same size as the human adrenal gland preproenkephalin mRNA
(Figure 6B). We estimate that this RNA represents about 0.01% of total
striatal mRNA and is thus close to the limit of detection in a cross-species
hybridisation. We were not able to detect this RNA in other parts of the
brain in which its abundance must be even lower. Even in striatum we could
not detect an mRNA of the size required to encode the reported precursor of
molecular weight 92,000.
DISCUSSION
We have used a synthetic oligonucleotide probe to detect bacterial
colonies containing human adrenal preproenkephalin cDNA; the signals obtained
were unequivocal even in a fairly high density colony screen. We also used
the oligonucleotide to prime cDNA synthesis. Labeled cDNA prepared in this
way was used as a probe both in colony screens and in transfer hybridisation
experiments; in both cases the probe detected non-enkephalin sequences. We
therefore conclude that it is preferable to use oligonucleotides as direct
hybridisation probes rather than as primers.
The human preproenkephalin cDNA sequence which we have determined is
generally similar to that recently described for bovine adrenal gland
preproenkephalin (27, 28). During the latter stages of this work Comb et at.
reported on the sequence of human adrenal gland preproenkephalin, also using
a cDNA clone derived from phaeochromocytoma mRNA (29). Their sequence
differs from ours in three positions none of which affects the predicted
amino acid sequence. While this manuscript was in preparation Noda et al.
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reported the sequence of the human preproenkephalin gene (30). Their
sequence differs from ours in just one position and shows that part of the
cDNA clone of Comb et al. results from an artefactual inversion. We have
sequenced both strands of our cDNA clone in the regions of these
discrepancies and are confident of our assignments. These differences could
reflect errors introduced during cloning or could result from polymorphisms
present in the human population. The latter possibility is particularly
likely as restriction fragment length polymorphisms are commonly detected in
the human population using the cloned preproenkephalin cDNA as a probe
(M. Hill and R. Williamson, personal communication).
In view of the general agreement between the three sequences we will
restrict our discussion to those areas in which our work adds to our
understanding of the enkephalin system, namely the disputed issues of the
size of the enkephalin precursor protein in human adrenal glands (25) and
the possibility that the pathway of enkephalin biosynthesis in the brain
might be quite different (23). We refer readers to other publications of
the preproenkephalin sequence (29, 30) for a full discussion of its
properties.
Most studies of enkephalin biosynthesis have used adrenal glands
because they are the richest source of these peptides (2). It has been a
disturbing possibility that such studies might prove to be relevant only to
the adrenal gland and that the pathway of enkephalin biosynthesis in brain
might be quite different, proceeding via a major precursor protein of
molecular weight 92,000 (23). Even in the case of the human adrenal gland
there are reports of abundant precursors with molecular weights of between
70,000 and 180,000 (25). Our in vitro translation studies of human adrenal
gland mRNA reveal no such precursors (Figure 1) and it is likely that the
previously reported precursors were in fact aggregates which were not
disrupted by the non-denaturing gel filtration conditions employed (25).
Our data on the translation of human adrenal gland mRNA are in agreement
with those of Dandekar and Sabol on the bovine system (24); they similarly
found no evidence for very high molecular weight precursors. The estimated
abundance and size of the precursor detected by in vitro translation are
sufficiently close to the figures obtained by cloning and sequencing to make
us confident that the sequenced cDNA represents the major preproenkephalin
mRNA in the human adrenal gland.
The relevance of studies on the adrenal gland to the biosynthesis of
enkephalin in the brain can still not be completely assessed. Our in vitro
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translation assay is not sufficiently sensitive to detect precursor synthesis
from brain mRNA so we have had to resort to transfer hybridisation
experiments using the adrenal gland cDNA as probe. Experiments with rat
adrenal gland mRNA show sufficient sequence homology between rat and human
to allow cross-species hybridisation and further showed that rat and human
adrenal gland preproenkephalin mRNAs are of essentially the same size
(Figure 6A). We could not detect an adrenal gland type mRNA in whole rat
brain (Figure 6A) but when mRNA isolated from various anatomical regions of
the brain was analysed it was possible to detect hybridisation to mRNA
extracted from the striatum (Figure 6B). This mRNA is the same size as
adrenal gland preproenkephalin mRNA and its detection only in the striatum
is significant as this is the part of the brain known to be richest in
enkephalin (31). This is a direct indication that work on the adrenal gland
is relevant to the brain and shows clearly that the gene encoding the
adrenal gland preproenkephalin is also expressed in brain striatum.
However, our data should not be taken to imply that the mRNA we have
detected encodes the only, or even the major, preproenkephalin in brain.
Recently a precursor to leu-enkephalin of molecular weight 29,000 has been
reported (32). The sequence of this preproenkephalin B is unrelated to that
of the preproenkephalin we have described and it remains possible that the
precursor of molecular weight 92,000 (23) is encoded by yet another
unrelated gene. The examples seen in other systems in which related proteins
are generated by differential splicing of the transcript of a single gene
or by the duplication of an ancestral gene with subsequent sequence
divergence are not necessarily helpful in this case because the active
enkephalin sequence is so short that it could have independently arisen
several times during evolution. Occassionally the occurrence of this
sequence will have conferred useful properties on the gene and, in the case
of the preproenkephalin described here, local duplications have resulted in
multiple enkephalin sequences within a single gene. This is evident from
the conservation seen in these sequences, with four of the first five
enkephalins using the same codons and with the fifth differing in only a
single residue. In other cases, for example S-endorphin (4), a single met-
enkephalin sequence confers opiate activity upon a larger peptide
containing no duplications. Given the potent activity and small size of
neuroactive peptides it seems likely that there are many other cases of
families of genes which are related not by their evolutionary background but
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